Acumen Pharmaceuticals’ Global Collaboration and License Agreement with Halozyme Therapeutics

Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

SensoDetect Aktiebolag’s Rights Offering

Moll Wenden advised SensoDetect Aktiebolag on the deal. SensoDetect Aktiebolag completed a rights issuance of units amounting to approximately SEK 19.4 million with preferential rights to...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Scandinavian ChemoTech AB’s Shares Offering

Moll Wenden advised Scandinavian ChemoTech AB on the deal. Scandinavian ChemoTech AB completed the issuance of shares amounting to approximately SEK 14.85 million. ChemoTech is a Swedish medical...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here